Peregrine reports positive cancer data

Peregrine Pharmaceuticals is posting positive data from two ongoing, mid-stage trials of its cancer therapy Cotara. The trial data assessed Cotara's safety and efficacy in treating patients with glioblastoma multiforme, a deadly form of brain cancer. The drug appeared to be safe and well tolerated, with no dose-limiting adverse events. And several volunteers surpassed the median expected survival time for relapsed GBM patients. 

"In view of the short expected survival time of approximately six months in this patient population, it is promising that we have early GBM patients in these trials who have survived past the six-monthtimeframe, with one patient now surviving 15 months post-treatment," said Steven W. King, president and CEO of Peregrine.

- check out the release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.